Date stringdate 2012-01-01 00:00:00 2023-12-31 00:00:00 | Stock_symbol stringlengths 1 5 | Article_title stringlengths 1 255 | Article stringlengths 1 342k |
|---|---|---|---|
2023-06-28 00:00:00+00:00 | ABBV | ABBV Factor-Based Stock Analysis | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-06-28 00:00:00+00:00 | ABBV | AbbVie Enters Oversold Territory | The DividendRank formula at Dividend Channel ranks a coverage universe of thousands of dividend stocks, according to a proprietary formula designed to identify those stocks that combine two important characteristics — strong fundamentals and a valuation that looks inexpensive. AbbVie Inc (Symbol: ABBV) presently has an... |
2023-06-28 00:00:00+00:00 | ABBV | What Will AbbVie Buy Next? | AbbVie (NYSE: ABBV) is facing a tough year ahead. The company's blockbuster drug Humira, which treats various autoimmune conditions such as rheumatoid arthritis, psoriasis, and Crohn's disease, will face biosimilar competition in the U.S. market starting in January 2023. Humira was a major revenue driver for AbbVie, co... |
2023-06-27 00:00:00+00:00 | ABBV | Quant Ratings Updated on 90 Stocks | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
It’s hard to believe that the second quarter – and the first half of the year – is now drawing to a close. While we’ve seen our fair share of volatility, the indices are ending the first half of 2023 on a strong note. As I write this, the S&P 500 is up 14.1... |
2023-06-27 00:00:00+00:00 | ABBV | AbbVie, Genmab Announces Positive Results From Phase 1/2 Trial Of Epcoritamab | (RTTNews) - AbbVie (ABBV) and Genmab (GMAB) announced positive results from the follicular lymphoma or FL cohort of the Phase 1/2 EPCORE NHL-1 clinical trial evaluating epcoritamab (DuoBody-CD3xCD20), an investigational T-cell engaging bispecific antibody administered subcutaneously.
The study cohort includes 128 adult... |
2023-06-27 00:00:00+00:00 | ABBV | 7 Stocks That Every 40-Year-Old Should Buy Today | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
While swinging for the fences brings excitement to the art of investing, slow and steady usually wins the race, which brings us to the best investments for 40-year-olds. Around this time frame, the emphasis centers on balance. You still want growth because ... |
2023-06-27 00:00:00+00:00 | ABBV | Top Stock Reports for Novo Nordisk, Home Depot & Walt Disney | Tuesday, June 27, 2023
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), The Home Depot, Inc. (HD) and The Walt Disney Company (DIS). These research reports have been hand-picked fro... |
2023-06-27 00:00:00+00:00 | ABBV | Is Global X SuperDividend U.S. ETF (DIV) a Strong ETF Right Now? | The Global X SuperDividend U.S. ETF (DIV) was launched on 03/11/2013, and is a smart beta exchange traded fund designed to offer broad exposure to the Style Box - All Cap Value category of the market.
What Are Smart Beta ETFs?
The ETF industry has traditionally been dominated by products based on market capitalization ... |
2023-06-27 00:00:00+00:00 | ABBV | Siemens and UCLA say data compromised in MOVEit data breach | Rewrites with comments from UCLA, FBI, background
FRANKFURT, June 27 (Reuters) - Siemens Energy ENR1n.DE and the University of California, Los Angeles (UCLA) said on Tuesday they were among victims of the MOVEit hack that has affected scores of corporations, governments and other institutions in recent weeks.
The hacke... |
2023-06-26 00:00:00+00:00 | ABBV | AbbVie (ABBV) Gets CHMP Positive Opinion for Atogepant Approval | AbbVie ABBV announced that the European Medicines Agency's (“EMA”) Committee for Medicinal Products for Human Use (“CHMP”) has given a positive opinion for atogepant. The CHMP has recommended approval of atogepant to treat migraine in adults. AbbVie’s atogepant is a once-daily, orally administered, CGRP receptor antago... |
2023-06-26 00:00:00+00:00 | ABBV | Notable ETF Inflow Detected - DGRO, JNJ, XOM, ABBV | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Core Dividend Growth ETF (Symbol: DGRO) where we have detected an approximate $88.1 million dollar inflow -- that's a 0.4% increase week over week in outstanding units (from 461,150,... |
2023-06-26 00:00:00+00:00 | ABBV | Should SPDR Portfolio S&P 500 High Dividend ETF (SPYD) Be on Your Investing Radar? | Looking for broad exposure to the Large Cap Value segment of the US equity market? You should consider the SPDR Portfolio S&P 500 High Dividend ETF (SPYD), a passively managed exchange traded fund launched on 10/21/2015.
The fund is sponsored by State Street Global Advisors. It has amassed assets over $6.28 billion, ma... |
2023-06-26 00:00:00+00:00 | ABBV | AbbVie (ABBV) Dips More Than Broader Markets: What You Should Know | AbbVie (ABBV) closed at $134.95 in the latest trading session, marking a -0.71% move from the prior day. This move lagged the S&P 500's daily loss of 0.45%. Elsewhere, the Dow lost 0.04%, while the tech-heavy Nasdaq added 3.58%.
Prior to today's trading, shares of the drugmaker had lost 1.19% over the past month. This ... |
2023-06-26 00:00:00+00:00 | ABBV | Validea Detailed Fundamental Analysis - ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-06-25 00:00:00+00:00 | ABBV | 1 Phenomenal High-Yield Dividend Stock You Can Buy and Hold Forever | What's the biggest knock against many high-yield dividend stocks? Probably that either the dividend or the share price is likely to sink sooner or later. That means that you often won't want to own these stocks for very long.
There are exceptions, though. Here's one phenomenal high-yield dividend stock you can buy and ... |
2023-06-24 00:00:00+00:00 | ABBV | ABBV Quantitative Stock Analysis | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-06-24 00:00:00+00:00 | ABBV | 4 Stocks That Can Turn $100,000 Into $500,000 by the Time You Retire | Are you truly ready to dive into a handful of stocks and then sit on them for years -- maybe even decades -- in search of future fortune?
It's OK if you aren't. For some people, navigating the market's every twist and turn and perpetually looking for the next hot stock is just their jam. For others, though, buying and ... |
2023-06-23 00:00:00+00:00 | ABBV | Daily Dividend Report: DTE,AIT,ABBV,LEN,MATX | The DTE Energy Board of Directors declared a $0.9525 per share dividend on its common stock payable Oct. 15, 2023, to shareholders of record at the close of business Sept. 18, 2023.
Applied Industrial Technologies Board of Directors has declared a quarterly cash dividend of $0.35 per common share, payable on August 31,... |
2023-06-23 00:00:00+00:00 | ABBV | AbbVie's Atogepant Secures Positive CHMP Opinion For The Preventive Treatment Of Migraine | (RTTNews) - Biopharmaceutical company AbbVie Inc. (ABBV) announced on Friday that the Committee for Medicinal Products for Human Use or CHMP of European Medicines Agency has given a positive opinion on the approval of Atogepant for the preventive treatment of migraine in adults.
If approved by the European Commission, ... |
2023-06-22 00:00:00+00:00 | ABBV | Guru Fundamental Report for ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-06-22 00:00:00+00:00 | ABBV | Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know | AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.
Shares of this drugmaker have returned -3% over the past month versus the Zacks S&P 500 composite's +4.3% change... |
2023-06-22 00:00:00+00:00 | ABBV | 2 No-Brainer Healthcare Stocks to Buy Right Now | Investors looking to participate in the stock market have a multitude of options, and it can sometimes be hard to separate the wheat from the chaff. But some companies look especially attractive, perhaps due to reasonable valuations, excellent prospects, or other factors.
Buying shares of such businesses and holding on... |
2023-06-21 00:00:00+00:00 | ABBV | Alleged Industrial Espionage Makes an Interesting Story | In this podcast, Motley Fool senior analyst Bill Mann and host Deidre Woollard discuss:
The high value of getting a leg up on the competition in the semiconductor industry.
If companies can do anything to keep secrets from leaking out.
Why Alphabet's adtech is attracting regulators' attention.
Motley Fool host Ricky Mu... |
2023-06-21 00:00:00+00:00 | ABBV | The Zacks Analyst Blog Highlights PepsiCo, AbbVie, Honeywell, Salesforce and Goldman Sachs | For Immediate Release
Chicago, IL – June 21, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: PepsiCo, Inc. PEP, AbbVie Inc... |
2023-06-20 00:00:00+00:00 | ABBV | Ready for a Rebound: 7 Blue-Chips Set to Regain Their Market Mojo | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
While the smaller-capitalization trades tend to attract the most speculative attention, for reliable upside prospects, investors may want to consider blue-chip stocks to buy. To better understand the motivation behind targeting these stalwarts, a baseball a... |
2023-06-20 00:00:00+00:00 | ABBV | Top Analyst Reports for PepsiCo, AbbVie & Honeywell | Tuesday, June 20, 2023
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including PepsiCo, Inc. (PEP), AbbVie Inc. (ABBV) and Honeywell International Inc. (HON). These research reports have been hand-picked from the... |
2023-06-20 00:00:00+00:00 | ABBV | ABBV Quantitative Stock Analysis | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-06-20 00:00:00+00:00 | ABBV | INSIGHT-Lab crunch: British science has nowhere to go | By Kate Holton
OXFORD, England, June 20 (Reuters) - For Ros Deegan, the thrill of raising $100 million to expand a biotech firm among the dreaming spires of Oxford was soon tempered: unable to find a bigger laboratory, she routinely had to work at home.
Not far away in the rival academic centre of Cambridge, biochemist... |
2023-06-19 00:00:00+00:00 | ABBV | Lilly's (LLY) Migraine Drug Fails Vis-a-Vis Pfizer's Nurtec ODT | Eli Lilly LLY announced that the phase IV CHALLENGE-MIG study, evaluating the efficacy and safety of its migraine drug Emgality against Pfizer‘s PFE Nurtec ODT, failed to meet primary endpoint of statistical superiority in achieving at least 50% reduction in monthly migraine headache days.
Emgality performed numericall... |
2023-06-19 00:00:00+00:00 | ABBV | Why Investors Should Care About Novartis' Latest Label Expansion -- It Could Mean Billions | Earlier this month, Novartis' (NYSE: NVS) smash-hit immunology medicine Cosentyx became the first drug within its class to be approved in the European Union to treat adult patients with moderate to severe hidradenitis suppurativa (HS).
What was the reasoning for the European Commission's approval of Cosentyx's sixth in... |
2023-06-18 00:00:00+00:00 | ABBV | Unlock the Potential of These 7 Cash-Flow Machines | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
There are several reasons to seek out high-cash-flow stocks. In the simplest terms, companies that generate strong cash flow can pay – and increase – dividends, develop new products and buy back shares among other things. Free cash flow is the cash a compan... |
2023-06-16 00:00:00+00:00 | ABBV | This Biotech Is About to Eat AbbVie's Market Share, but Is It a Buy? | Soon enough, there's a big chance that the plucky biotech Coherus Biosciences (NASDAQ: CHRS) is going to be eating AbbVie's (NYSE: ABBV) lunch. Assuming it does, it's not going to be stealing a fry from the corner of AbbVie's plate -- it's going for a big-mouth chomp of the cheeseburger with all the fixings. And there'... |
2023-06-16 00:00:00+00:00 | ABBV | Notable ETF Inflow Detected - XLV, ABBV, DHR, BMY | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the The Health Care Select Sector SPDR Fund (Symbol: XLV) where we have detected an approximate $350.4 million dollar inflow -- that's a 0.9% increase week over week in outstanding units (from 3... |
2023-06-16 00:00:00+00:00 | ABBV | AbbVie's (ABBV) Skyrizi Meets Ulcerative Colitis Study Goals | AbbVie, Inc. ABBV announced top-line data from the phase III maintenance study, COMMAND, which evaluated its IL-23 drug Skyrizi (risankizumab) in adult patients with moderately to severely active ulcerative colitis (“UC”) indication.
Data from the COMMAND study showed that a significantly higher proportion of patients ... |
2023-06-16 00:00:00+00:00 | ABBV | Validea Detailed Fundamental Analysis - ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-06-16 00:00:00+00:00 | ABBV | Roche's cancer therapy gets US FDA nod, heating up competition with AbbVie | By Mariam Sunny and Pratik Jain
June 16 (Reuters) - The U.S. Food and Drug Administration (FDA) greenlighted Roche Holding AG's ROG.S experimental therapy to treat a type of advanced blood cancer, nearly a month after the approval of a rival therapy from AbbVie Inc ABBV.N.
Roche's Columvi, an antibody-based therapy che... |
2023-06-15 00:00:00+00:00 | ABBV | How Has Merck Stock Performed During The 2022-23 Inflation Shock? | Merck stock (NYSE: MRK) currently trades at $110 per share, roughly 43% above its level in March 2021, and it looks fully valued. Merck saw its stock trading at around $91 in late June 2022, just before the Fed started increasing rates, and is now 20% above that level. The stock has gained 28% since September 2022 comp... |
2023-06-15 00:00:00+00:00 | ABBV | Notable Thursday Option Activity: PG, MARA, ABBV | Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Procter & Gamble Company (Symbol: PG), where a total volume of 25,957 contracts has been traded thus far today, a contract volume which is representative of approximately 2.6 million underlying shares (... |
2023-06-15 00:00:00+00:00 | ABBV | Abbvie, Coherus agree to resolve dispute over Humira biosimilar | June 15 (Reuters) - Coherus BioSciences Inc CHRS.O said on Thursday it had agreed to resolve a dispute over its plans to launch a lower-priced version of AbbVie Inc's ABBV.N Humira, its blockbuster rheumatoid arthritis drug.
Earlier this month, Coherus had said it would launch a biosimilar version of the world's bigges... |
2023-06-14 00:00:00+00:00 | ABBV | ABBV Factor-Based Stock Analysis | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-06-13 00:00:00+00:00 | ABBV | Is SPDR Portfolio S&P 500 High Dividend ETF (SPYD) a Strong ETF Right Now? | The SPDR Portfolio S&P 500 High Dividend ETF (SPYD) was launched on 10/21/2015, and is a smart beta exchange traded fund designed to offer broad exposure to the Style Box - Large Cap Value category of the market.
What Are Smart Beta ETFs?
Market cap weighted indexes were created to reflect the market, or a specific seg... |
2023-06-13 00:00:00+00:00 | ABBV | Mustang (MBIO) Up 9% on Rare Blood Cancer Study's Upbeat Data | Shares of Mustang Bio MBIO were up 9.2% on Jun 12 after management announced updated results from a cohort of an ongoing single-institution phase I/II study evaluating its lead clinical candidate MB-106 in patients with Waldenstrom macroglobulinemia (“WM”), a rare form of blood cancer.
Data from the study showed that t... |
2023-06-13 00:00:00+00:00 | ABBV | Ironwood (IRWD), AbbVie Get FDA Nod for Linzess Label Expansion | Ironwood IRWD announced that the FDA has approved Linzess (linaclotide) as a once-daily treatment for functional constipation in pediatric patients aged 6-17 years. This approval for the new indication marks a milestone for IRWD as Linzess becomes the first and only FDA-approved prescription therapy for functional cons... |
2023-06-12 00:00:00+00:00 | ABBV | AbbVie (ABBV) Stock Sinks As Market Gains: What You Should Know | In the latest trading session, AbbVie (ABBV) closed at $137.73, marking a -0.33% move from the previous day. This move lagged the S&P 500's daily gain of 0.93%. Elsewhere, the Dow gained 0.56%, while the tech-heavy Nasdaq added 1.71%.
Prior to today's trading, shares of the drugmaker had lost 6.1% over the past month. ... |
2023-06-12 00:00:00+00:00 | ABBV | XPeng's New EV Is a Hit, but This Biotech Stock Is Leaving It in the Dust | Investors appeared to be in a good mood on Monday morning. Based on stock index futures, it was likely that major market benchmarks would hold onto their gains from last week and even make modest moves higher. The Nasdaq Composite seemed particularly well positioned, with indications suggesting a rise of as much as hal... |
2023-06-11 00:00:00+00:00 | ABBV | 7 Top Blue-Chip Stocks to Buy in June 2023 | InvestorPlace - Stock Market News, Stock Advice & Trading Tips
The market probably feels like the movie Groundhog’s Day for many investors. The major indexes continue to trade within a range, which is frustrating both bulls and bears. And with the market entering what is usually a quieter period, it may stay this way u... |
2023-06-11 00:00:00+00:00 | ABBV | Guru Fundamental Report for ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-06-10 00:00:00+00:00 | ABBV | Guru Fundamental Report for ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-06-10 00:00:00+00:00 | ABBV | Better Long-Term Buy: AbbVie or Novo Nordisk? | Pharmaceutical companies Novo Nordisk (NYSE: NVO) and AbbVie (NYSE: ABBV) seem to be headed in separate directions.
Denmark-based Novo Nordisk, thanks to growing sales of diabetes drug Ozempic and obesity therapy Wegovy, is predicting sales to grow between 24% to 30% and operating profit to rise 28% to 34% this year.
A... |
2023-06-09 00:00:00+00:00 | ABBV | Validea Detailed Fundamental Analysis - ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-06-09 00:00:00+00:00 | ABBV | Here is What to Know Beyond Why AbbVie Inc. (ABBV) is a Trending Stock | AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.
Shares of this drugmaker have returned -6.1% over the past month versus the Zacks S&P 500 composite's +4% change... |
2023-06-09 00:00:00+00:00 | ABBV | U.S. government sets penalties on 43 drugs over price hikes | By Patrick Wingrove
June 9 (Reuters) - The Biden administration on Friday announced it would impose inflation penalties on 43 drugs for the third quarter of 2023, having fined 27 earlier this year, in a move it said would lower costs for older Americans by as much as $449 per dose.
Drugmakers hiked the price of these 4... |
2023-06-08 00:00:00+00:00 | ABBV | Interesting ABBV Put And Call Options For July 28th | Investors in AbbVie Inc (Symbol: ABBV) saw new options become available today, for the July 28th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the ABBV options chain for the new July 28th contracts and identified one put and one call contract of particular interest.
The put contrac... |
2023-06-08 00:00:00+00:00 | ABBV | First Trust Morningstar Dividend Leaders Index Fund Experiences Big Outflow | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the First Trust Morningstar Dividend Leaders Index Fund (Symbol: FDL) where we have detected an approximate $170.7 million dollar outflow -- that's a 3.6% decrease week over week (from 138,050,0... |
2023-06-08 00:00:00+00:00 | ABBV | Guru Fundamental Report for ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-06-08 00:00:00+00:00 | ABBV | Is ProShares S&P 500 Dividend Aristocrats ETF (NOBL) a Strong ETF Right Now? | A smart beta exchange traded fund, the ProShares S&P 500 Dividend Aristocrats ETF (NOBL) debuted on 10/09/2013, and offers broad exposure to the Style Box - Large Cap Value category of the market.
What Are Smart Beta ETFs?
Market cap weighted indexes were created to reflect the market, or a specific segment of the mark... |
2023-06-07 00:00:00+00:00 | ABBV | Validea Detailed Fundamental Analysis - ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-06-07 00:00:00+00:00 | ABBV | Vertex (VRTX) Stock Poised Well for Growth in 2023: Here's Why | Vertex Pharmaceuticals Incorporated VRTX enjoys a dominant position in the cystic fibrosis (CF) market. Vertex’s CF sales continue to grow, driven by its triple therapy, Trikafta/Kaftrio. New reimbursement agreements in ex-U.S. markets and label expansions to younger age groups are driving Trikafta/Kaftrio sales higher... |
2023-06-06 00:00:00+00:00 | ABBV | $300 a Month in These 3 Stocks Could Make You a Millionaire by Retirement | What is the link between the theoretical physicist Albert Einstein and investing? At first blush, newer investors may not be aware there was such a link between the two topics of discussion.
Einstein is sometimes attributed with saying: "Compound interest is the eighth wonder of the world. He who understands it, earns ... |
2023-06-06 00:00:00+00:00 | ABBV | IBM, CVX, or ABBV: Which Dividend Aristocrat Stock is the Most Compelling Pick? | During these uncertain times, investors seek reliable dividend-paying companies that can generate stable income. Dividend aristocrats are companies that have increased their dividends for at least 25 consecutive years and are preferred by investors looking for passive income for their ability to build wealth over time.... |
2023-06-05 00:00:00+00:00 | ABBV | Validea Detailed Fundamental Analysis - ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-06-04 00:00:00+00:00 | ABBV | Guru Fundamental Report for ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-06-03 00:00:00+00:00 | ABBV | Guru Fundamental Report for ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-06-02 00:00:00+00:00 | ABBV | Is Merck Stock A Better Pick Over ABBV? | We believe that AbbVie stock (NYSE: ABBV) is a better pick than its industry peer, Merck stock (NYSE: MRK). MRK stock trades at a slightly higher valuation of 4.8x trailing revenues, compared to 4.2x for AbbVie, and this valuation gap will likely narrow over time in favor of AbbVie, in our view. Looking at stock retur... |
2023-06-01 00:00:00+00:00 | ABBV | 7 Best Dividend Stocks to Buy Now in June 2023 | Today, I provide my seven best dividend stocks to buy for the month of June. Dividend stocks are a great way to add balance and passive income to a long-term investing portfolio. Compound interest is often called the eighth wonder of the world, and dividends are a great way to accelerate your wealth.
Two of my favorite... |
2023-06-01 00:00:00+00:00 | ABBV | Why AbbVie and Amgen Are Moving Lower Today | What happened
Shares of the immunology juggernaut AbbVie (NYSE: ABBV) were down by 4% on sky-high volume as of 11 a.m. ET Thursday. That's equivalent to a $7 billion drop in market capitalization.
What's spooking investors this morning? The big loss came after Coherus Biosciences announced a partnership with billionair... |
2023-06-01 00:00:00+00:00 | ABBV | AstraZeneca (AZN) Discontinues Brazikumab Development | AstraZeneca AZN announced the discontinuation of studies on its monoclonal antibody targeting IL23, brazikumab. The candidate was being studied for two indications, Crohn’s disease (CD) and ulcerative colitis (UC), under the inflammatory bowel disease (IBD) development program.
A phase IIb/III INTREPID study was evalua... |
2023-06-01 00:00:00+00:00 | ABBV | Coherus BioSciences to launch Humira biosimilar at 85% discount | Updates AbbVie shares, adds Amgen shares in paragraph 7, background on competitors in paragraphs 5-6
June 1 (Reuters) - Coherus BioSciences Inc CHRS.O said on Thursday it plans to launch a biosimilar of AbbVie Inc's ABBV.N Humira in July at a list price of $995 per carton, representing a discount of about 85% from the ... |
2023-06-01 00:00:00+00:00 | ABBV | Guru Fundamental Report for ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-06-01 00:00:00+00:00 | ABBV | AstraZeneca to stop developing Crohn's disease drug | Adds background on drug and AbbVie funding in paragraphs 3 and 4
June 1 (Reuters) - British drugmaker AstraZeneca AZN.L said on Thursday it would stop developing its drug brazikumab to treat inflammatory bowel diseases, including Crohn's disease and ulcerative colitis.
The company said the discontinuation was due to a ... |
2023-05-31 00:00:00+00:00 | ABBV | SPLG, BRK.B, MRK, ABBV: ETF Inflow Alert | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the SPDR Portfolio S&P 500 ETF (Symbol: SPLG) where we have detected an approximate $108.7 million dollar inflow -- that's a 0.6% increase week over week in outstanding units (from 347,600,000 t... |
2023-05-31 00:00:00+00:00 | ABBV | Validea Detailed Fundamental Analysis - ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-05-31 00:00:00+00:00 | ABBV | What's Ahead for the 10 Stocks That Have Driven Over 80% of U.S. Market Returns So Far in 2023 | So far, 2023 has been a remarkable year for U.S. equities markets, with the S&P 500 index staging a 10% rally, defying recession fears. However, behind this seemingly positive performance lies a concerning trend.
A select group of technology giants, commonly referred to as the ‘FAANG’ megacaps [minus Netflix (US:NFLX)... |
2023-05-31 00:00:00+00:00 | ABBV | AbbVie Says Upadacitinib 30 Mg Meets Primary Goals In SLE Patients In Mid-stage Study | (RTTNews) - AbbVie Inc. (ABBV), a clinical-stage pharmaceutical company, Wednesday announced the results of its phase 2 SLEek study evaluating upadacitinib (RINVOQ 30 mg), alone and in combination with ABBV-599 high dose (elsubrutinib 60 mg) for systemic lupus erythematosus or SLE in adults.
In the phase 2 of the study... |
2023-05-30 00:00:00+00:00 | ABBV | Should Invesco Dynamic Large Cap Value ETF (PWV) Be on Your Investing Radar? | Launched on 03/03/2005, the Invesco Dynamic Large Cap Value ETF (PWV) is a passively managed exchange traded fund designed to provide a broad exposure to the Large Cap Value segment of the US equity market.
The fund is sponsored by Invesco. It has amassed assets over $734.77 million, making it one of the average sized ... |
2023-05-29 00:00:00+00:00 | ABBV | Should You Pick AbbVie Stock Over LLY? | We believe that AbbVie stock (NYSE: ABBV) is a better pick than its industry peer, Eli Lilly stock (NYSE: LLY). LLY stock trades at a higher valuation of 14.6x trailing revenues, compared to just 4.2x for AbbVie, and this valuation gap will likely narrow over time in favor of AbbVie, in our view. Looking at stock retu... |
2023-05-29 00:00:00+00:00 | ABBV | Guru Fundamental Report for ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-05-29 00:00:00+00:00 | ABBV | AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know | AbbVie (ABBV) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near future.
Over the past month, shares of this drugmaker have returned -9%, compared to the Zacks S&P 500 composite's +3.9%... |
2023-05-26 00:00:00+00:00 | ABBV | Guru Fundamental Report for ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-05-25 00:00:00+00:00 | ABBV | 2 Dividend Kings on Sale That Are Yielding More Than 4% | Dividend Kings have excellent track records for dividend growth, and are often seen as some of the safest income investments to own. Two dividend growth stocks that may look tempting and that investors may want to take a closer look at today are AbbVie (NYSE: ABBV) and 3M (NYSE: MMM). They have been struggling this yea... |
2023-05-25 00:00:00+00:00 | ABBV | 2 Top Dividend Kings to Buy for the Long Haul | The market had a difficult 2022. Last year revealed the importance of having safe stocks in your portfolio during times of market volatility.
Enter dividend stocks. What's better than companies that have a track record of consistently paying and increasing dividends? And the most impressive of them all are Dividend Kin... |
2023-05-25 00:00:00+00:00 | ABBV | The Zacks Analyst Blog Highlights AbbVie, Intel, Qualcomm, Regeneron and CME Group | For Immediate Release
Chicago, IL – May 25, 2023 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: AbbVie Inc. ABBV, Intel Corp. ... |
2023-05-25 00:00:00+00:00 | ABBV | Should First Trust Morningstar Dividend Leaders ETF (FDL) Be on Your Investing Radar? | Looking for broad exposure to the Large Cap Value segment of the US equity market? You should consider the First Trust Morningstar Dividend Leaders ETF (FDL), a passively managed exchange traded fund launched on 03/09/2006.
The fund is sponsored by First Trust Advisors. It has amassed assets over $4.72 billion, making ... |
2023-05-24 00:00:00+00:00 | ABBV | Oversold Conditions For AbbVie | Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.... |
2023-05-24 00:00:00+00:00 | ABBV | Top Research Reports for AbbVie, Intel & Qualcomm | Wednesday, May 24, 2023
The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), Intel Corp. (INTC) and Qualcomm Inc. (QCOM). These research reports have been hand-picked from the roughly 70 re... |
2023-05-24 00:00:00+00:00 | ABBV | Noteworthy Wednesday Option Activity: COIN, ABNB, ABBV | Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Coinbase Global Inc (Symbol: COIN), where a total of 93,518 contracts have traded so far, representing approximately 9.4 million underlying shares. That amounts to about 72.5% of COIN's average daily trading vol... |
2023-05-23 00:00:00+00:00 | ABBV | Ironwood (IRWD) to Acquire VectivBio for $1B, Stock Up 3.6% | Ironwood IRWD announced a definitive agreement to acquire VectivBio VECT, a Switzerland-based biotech company, focused on the development of treatments for severe and rare gastrointestinal conditions.
Shares of Ironwood and VectivBio surged 3.6% and 38.6%, respectively, following the news.
The all-cash transaction is v... |
2023-05-23 00:00:00+00:00 | ABBV | Noteworthy ETF Outflows: IXJ, ABBV, PFE, ELV | Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the iShares Global Healthcare ETF (Symbol: IXJ) where we have detected an approximate $72.8 million dollar outflow -- that's a 1.7% decrease week over week (from 48,650,000 to 47,800,000). Among... |
2023-05-22 00:00:00+00:00 | ABBV | Why Ironwood Pharmaceuticals Stock Bumped Higher Today | What happened
Ironwood Pharmaceuticals (NASDAQ: IRWD) is choosing to go the acquisition route to grow its business. On Monday, the company announced it has agreed to acquire clinical-stage biotech VectivBio Holding (NASDAQ: VECT). Investors were clearly warm to that move, as they subsequently traded up Ironwood stock b... |
2023-05-22 00:00:00+00:00 | ABBV | Is Invesco Dynamic Large Cap Value ETF (PWV) a Strong ETF Right Now? | A smart beta exchange traded fund, the Invesco Dynamic Large Cap Value ETF (PWV) debuted on 03/03/2005, and offers broad exposure to the Style Box - Large Cap Value category of the market.
What Are Smart Beta ETFs?
Products that are based on market cap weighted indexes, which are strategies designed to reflect a specif... |
2023-05-22 00:00:00+00:00 | ABBV | Should You Invest in the Invesco Dynamic Pharmaceuticals ETF (PJP)? | Launched on 06/23/2005, the Invesco Dynamic Pharmaceuticals ETF (PJP) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Pharma segment of the equity market.
An increasingly popular option among retail and institutional investors, passively managed ETFs offer low costs,... |
2023-05-22 00:00:00+00:00 | ABBV | AbbVie (ABBV) Gets FDA Nod for Lymphoma Drug Epcoritamab | AbbVie ABBV and partner Genmab GMAB announced that the FDA has granted accelerated approval to their T-cell engaging bispecific antibody epcoritamab for treating relapsed/refractory diffuse large B-cell lymphoma (DLBCL). The new drug will be marketed by the trade name of Epkinly. Continued approval for this indication... |
2023-05-22 00:00:00+00:00 | ABBV | Guru Fundamental Report for ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-05-20 00:00:00+00:00 | ABBV | 3 Relatively Safe Stocks to Buy if a Recession Is on the Way | We don't have a modern-day Paul Revere riding a horse through the streets shouting that a recession is coming. But we don't need one, as there are plenty of economists, analysts, and even the Federal Reserve warning that a recession is likely in 2023.
But just because a recession may be on the way, investors don't have... |
2023-05-20 00:00:00+00:00 | ABBV | 3 No-Brainer Dividend Stocks to Buy With $1,000 Right Now | Paralysis analysis. It's what happens when you have so many alternatives to evaluate that overthinking causes you to be unable to make a decision.
This condition can easily occur when selecting dividend stocks. Over 4,000 stocks traded on U.S. exchanges offer dividends. But income-seeking investors don't have to suffer... |
2023-05-19 00:00:00+00:00 | ABBV | Pharma Stock Roundup: FDA Nod to ABBV's Rinvoq for New Indication & Other Updates | This week an FDA panel voted in favor of approving Pfizer’s PFE experimental maternal RSV vaccine candidate. The FDA approved AbbVie’s ABBV Rinvoq for its seventh indication, Crohn’s Disease and granted Fast Track Designation to Bayer’s BAYRY asundexian atrial fibrillation program. Roche’s RHHBY BTK inhibitor, fenebrut... |
2023-05-19 00:00:00+00:00 | ABBV | US FDA approves Genmab-AbbVie's blood cancer therapy | May 19 (Reuters) - The U.S. Food and Drug Administration has approved AbbVie Inc ABBV.N and Danish drugmaker Genmab's GMAB.CO experimental blood cancer therapy for adult patients who have received at least two prior lines of treatment, the companies said on Friday.
(Reporting by Mariam Sunny in Bengaluru; Editing by Sh... |
2023-05-19 00:00:00+00:00 | ABBV | AbbVie's (ABBV) Rinvoq Gets FDA Nod to Treat Crohn's Disease | AbbVie ABBV announced the FDA approval of its immunology drug, Rinvoq (upadacitinib), a once-daily pill for the treatment of adults with moderately to severely active Crohn's disease who have had an inadequate response or intolerance to one or moretumor necrosis factor blockers. Rinvoq is one of AbbVie’s newer drugs. T... |
2023-05-19 00:00:00+00:00 | ABBV | Guru Fundamental Report for ABBV | Below is Validea's guru fundamental report for ABBVIE INC (ABBV). Of the 22 guru strategies we follow, ABBV rates highest using our P/B Growth Investor model based on the published strategy of Partha Mohanram. This growth model looks for low book-to-market stocks that exhibit characteristics associated with sustained f... |
2023-05-18 00:00:00+00:00 | ABBV | Should Schwab U.S. Dividend Equity ETF (SCHD) Be on Your Investing Radar? | The Schwab U.S. Dividend Equity ETF (SCHD) was launched on 10/20/2011, and is a passively managed exchange traded fund designed to offer broad exposure to the Large Cap Value segment of the US equity market.
The fund is sponsored by Charles Schwab. It has amassed assets over $45.19 billion, making it one of the largest... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.